Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...
Researchers tested the peptide BLMP6 in breast cancer models. The peptide demonstrated selective binding to metastatic cells ...
Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes M6P ...
Meanwhile, peroxisome proliferation-activated receptors (PPARs) are obesity drug targets in their own right: activating them can reduce inflammation and restore insulin sensitivity. But molecules that ...
Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results